Usually, studies obtain two RNA‐Seq datasets from PNEN patients and analyze the immune characteristics to determine the immune profile of this heterogeneous tumor, quantifying the expression of 10 immune markers (IL‐16, IRF4, LRG1, MUC1, CXCL9, CCL19, CR2, PIR, CD79A, and TCF21) via immunochemistry and CD4, CD8, and CD163 distribution intratumorally and peritumorally based on immunofluorescence [9]. The gene discussed is CD4; the disease is neoplasm.